Studies in other cancer types have reported that complement activation promotes tumour growth and suppresses anti-tumour immunity including levels of CD8+ and CD4+ TILs58–61 which is consistent with the inferior survival outcomes in the CD3+ TIL-low UPS and DDLPS patients in our cohort. Here, CD8A is linked to cancer.